How should capital read Raleigh-Durham in 2026 — as a Tier 2 life sciences reset market, an advanced-manufacturing industrial play, a zero-pipeline office recovery, or a combination of all three?

Raleigh-Durham is not a generic Sun Belt growth story. It is a research-economy market where the allocation decision depends entirely on asset class and submarket. Industrial is the cleanest signal: moderate vacancy, positive rent growth, and a pipeline that is building toward but not yet overwhelming absorption. Office is a supply-reset story with sharp bifurcation — Six Forks and Downtown Durham are investable while RTP/I-40 legacy campus space faces structural headwinds. Life sciences lab is a patient-capital opportunity with pipeline discipline already restored and a real tenant ecosystem behind the vacancy number. Multifamily is normalizing: a historically large delivery wave is now decelerating and the 2026 pipeline is roughly half the 2024 peak. Retail is persistently tight and offers one of the cleanest cash-flow reads in the Carolinas.

The Triangle rewards capital that underwriters by submarket and asset type rather than betting on metro-level momentum. The risk is paying for specialization before the lab market clears or treating the metro's supply reset as if it were already a tightening market.

• Zero office pipeline. No other Sun Belt market of comparable size has a fully shut office construction pipeline. The supply-reset is real: 22.9% vacancy range-bound for six quarters is a stabilization signal, not a deterioration story.
• Life sciences anchor depth is institutional-grade. Seven of the top 10 global CROs operate in the Triangle. Novo Nordisk ($4.1B), Biogen ($2.0B), FUJIFILM Diosynth, IQVIA, and GlaxoSmithKline are not speculative anchors — they are multi-decade embedded tenants. The 32.3% lab vacancy reflects a supply cycle, not cluster deterioration.
• Advanced manufacturing is growing. The Eastern Wake and Johnston County industrial corridor is absorbing last-mile and light-manufacturing demand at 6.4% vacancy — tighter than Charlotte's 8.1% and significantly tighter than Atlanta's 9.0%. This is the physical-economy leg of a market often described only through its knowledge-economy story.
• Retail is the quiet defensible leg. Sub-3% vacancy for four consecutive years is not an accident. The Research Triangle employment base and sustained in-migration from California and the Northeast create a consumer base with above-average spending capacity and below-average retail supply growth.
• Pipeline deceleration in multifamily arrives in 2026. The delivery wave is cresting. ~12,000 units in 2025 versus a 2026 pipeline of ~6,000 units means the first annual vacancy improvement since 2021 is likely. The timing is now rather than speculative.

• Do not underwrite RTP/I-40 office as if it shares Six Forks rents or Downtown Durham vacancy. The two ends of the market are approximately 14 percentage points apart in vacancy. Metro-level averages obscure the size of this spread.
• Life sciences lab sublease supply is real. Overall vacancy (32.3%) includes a meaningful sublease component driven by Charles River Labs. Direct vacancy (26.5%) is the better underwriting number. Even direct vacancy means the market is not tight — it is a buyer's market requiring patience.
• Industrial rent growth is positive but modest. +0.9% YoY is not a pricing-power story. It is a supply-absorption story where newer inventory commands a premium over older flex product. The CBRE ($10.32/SF) and Savills/Avison Young ($10.17/SF) data diverge on asking rent and under-construction pipeline figures — different tracking universes, both public, not fully reconciled; underwriting should use the conservative end.
• Multifamily is not yet a rent-growth story. ~92% occupancy is healthy but not scarcity-level. The thesis is pipeline deceleration and normalization, not a demand shock. Investors who need rent growth in their first hold year are underwriting the wrong part of the cycle.
• Retail cap rate data is limited. Lee & Associates Q3 2025 reported Raleigh retail cap rates at 6.8% and Durham at 8.8% — a spread that reflects market depth and product quality differences inside the same metro. Q4 2025 cap rate data was not confirmed from a single accessible public source as of this writing.

• Raleigh-Durham wins for capital that wants Carolinas specialization over scale: long-duration life sciences and advanced-manufacturing exposure, flight-to-quality office in proven winner submarkets, and durable retail cash flow in a market that has not broken its vacancy floor in four years.
• It is strongest for: light-industrial and advanced-manufacturing specialists targeting Eastern Wake/Johnston County; selective office buyers with reset-basis conviction in Six Forks or Downtown Durham; opportunistic lab investors willing to buy through the current sublease overhang; and patient multifamily capital timed to the pipeline deceleration.
• It is weaker for: investors who need a near-term lab lease-up thesis, broad RTP/I-40 office buyers without significant basis discount, or capital whose return case depends on immediate rent acceleration in any asset class.
• Relative to Charlotte, Raleigh-Durham offers a cleaner supply reset, tighter industrial vacancy, and unique life sciences optionality at the cost of less institutional liquidity and smaller logistics scale. The practical choice is specialization versus depth. See Charlotte vs Raleigh-Durham for the head-to-head.

All values sourced from data/properties.db market observations; as-of dates as noted.

Note: Life sciences data is Q2 2025 — the best publicly accessible ungated period for this asset class as of this writing. Q3 2025 Savills life sciences vacancy (23.9%) uses a narrower tracked universe and is not directly comparable to the C&W 32.3% figure. Industrial total inventory SF is not confirmed from a single accessible Q4 2025 public source (REBusinessOnline cited ~81M SF as of early 2024; the figure has grown given active delivery pipeline but no single citable source confirms the current number).

The Triangle sits in the Tier 2 bucket in the national life sciences hierarchy. See National Life Sciences Capital Allocation 2026 for the full cross-cluster read. The key Raleigh-Durham-specific point is that the pipeline collapse (from 901,650 SF under construction in Q2 2024 to 0 SF in Q2 2025) is the most important structural change in the market — it is what separates the Triangle from a market still working through active spec delivery. That pipeline discipline, combined with the anchor-tenant depth described above, is why the market is interesting for opportunistic and value-oriented capital rather than being dismissed as an oversupplied secondary node.

• Analyses Hub
• Raleigh-Durham
• Charlotte and Raleigh-Durham
• Charlotte vs Raleigh-Durham
• Raleigh-Durham Geography Hub
• Carolinas Geography Hub
• National Life Sciences Capital Allocation 2026
• CRE Investment Strategy
• Office Bifurcation
• Life Sciences Cluster Geography
• Eastern Wake and Johnston County Corridor
• Six Forks and North Hills
• Downtown Durham
• RTP and I-40 Corridor

• Raleigh-Durham Market Intelligence 2025